Dasatinib is a safe therapy for imatinib-resistant patients with chronic-phase CML

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷 / 9期
关键词：
D O I：
10.1038/ncponc0891
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：503 / 503
相关论文
共 50 条
  • [21] Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
    Shah, Neil P.
    Rousselot, Philippe
    Schiffer, Charles
    Rea, Delphine
    Cortes, Jorge E.
    Milone, Jorge
    Mohamed, Hesham
    Healey, Diane
    Kantarjian, Hagop
    Hochhaus, Andreas
    Saglio, Giuseppe
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (09) : 869 - 874
  • [22] Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).
    Khoury, Hanna Jean
    Mauro, Michael J.
    Matloub, Yousif
    Chen, Tai-Tsang
    Bahceci, Erkut
    Deininger, Michael
    BLOOD, 2009, 114 (22) : 463 - 464
  • [23] Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
    Usala, Emilio
    CLINICAL MANAGEMENT ISSUES, 2011, 5 : 27 - 30
  • [24] Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML
    Zhu, Guang-rong
    Ji, Ou
    Ji, Jian-min
    Zhang, Ya-cheng
    Wu, Yu
    Yu, Hui
    Jiang, Peng-Jun
    Shen, Qun
    ACTA HAEMATOLOGICA, 2012, 127 (03) : 152 - 155
  • [25] Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party
    Lee, Jeong-Ok
    Kim, Inho
    Chung, Joo-Seop
    Kim, Yeo-Kyeoung
    Yhim, Ho-Young
    Kim, Dae-Young
    Do, Young-Rok
    Seong, Chu-Myong
    Nam, Seung-Hyun
    Kim, Sung-Hyun
    Lee, Jae-Hoon
    Park, Jinny
    Kim, Jin Seok
    Min, Yoo-Hong
    Sohn, Sang Kyun
    Joo, Young Don
    Bae, Sung-Hwa
    Oh, Sukjoong
    Zang, Dae Young
    Lee, Hong Ghi
    Yoon, Sung-Soo
    Park, Seonyang
    BLOOD, 2012, 120 (21)
  • [26] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
    Hoyle, Martin
    Rogers, Gabriel
    Moxham, Tiffany
    Liu, Zulian
    Stein, Ken
    VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
  • [27] Drug synergies for imatinib-resistant CML
    Darren J. Burgess
    Nature Reviews Cancer, 2012, 12 (11) : 737 - 737
  • [28] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or-intolerant chronic phase and accelerated phase Philadelphia-positive chronic myelogenous leukemia
    Giles, F.
    Le Coutre, P.
    Bhalla, K.
    Rosti, G.
    Ossenkoppele, G.
    Alimena, G.
    Weitzman, A.
    Haque, A.
    Shou, Y.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 206 - 207
  • [29] Dasatinib therapy of patients with chronic myeloid leukemia resistant to imatinib therapy
    Khoroshko, N. D.
    Vinogradova, O. Yu.
    Turkina, A. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2008, 53 (03): : 29 - 34
  • [30] Clinical and Patient-Reported Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia
    Ionova, Tatyana I.
    Nikitina, Tatiana P.
    Gritsenko, Taras A.
    Ivanova, Valentina L.
    Kuchma, Galina B.
    Shnaider, Tatyana V.
    Fedorenko, Denis A.
    Kurbatova, Kira A.
    Novik, Andrei A.
    BLOOD, 2012, 120 (21)
12345